Segui
Giuseppe Tonini
Giuseppe Tonini
Professore ordinario di Oncologia, Università Campus Bio-Medico di Roma
Email verificata su unicampus.it
Titolo
Citata da
Citata da
Anno
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
25842010
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular …
C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ...
The Lancet Oncology 16 (13), 1306-1315, 2015
11352015
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
11232014
Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr)
E Cacciari, S Milani, A Balsamo, E Spada, G Bona, L Cavallo, F Cerutti, ...
Journal of endocrinological investigation 29, 581-593, 2006
8472006
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
7122009
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
6492017
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial …
R Gralla, M Lichinitser, S Van Der Vegt, H Sleeboom, J Mezger, ...
Annals of Oncology 14 (10), 1570-1577, 2003
6442003
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy …
P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ...
Journal of Clinical Oncology 23, 6865-6872, 2005
5652005
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
J Clin Oncol 27 (16), 2622-2629, 2009
5082009
Gut microbiota and cancer: from pathogenesis to therapy
S Vivarelli, R Salemi, S Candido, L Falzone, M Santagati, S Stefani, ...
Cancers 11 (1), 38, 2019
4822019
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ...
Clinical Cancer Research 9 (8), 2893-2897, 2003
4722003
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally …
D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ...
Annals of Oncology 32 (8), 994-1004, 2021
4542021
Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study
M Muscaritoli, S Lucia, A Farcomeni, V Lorusso, V Saracino, C Barone, ...
Oncotarget 8 (45), 79884, 2017
4012017
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
3792007
Italian cross-sectional growth charts for height, weight and BMI (6–20 y)
E Cacciari, S Milani, A Balsamo, F Dammacco, F De Luca, F Chiarelli, ...
European journal of clinical nutrition 56 (2), 171-180, 2002
3792002
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ...
Clinical Cancer Research 8 (5), 1080-1084, 2002
3582002
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
3092008
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer
TC Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, G Tonini
Journal of clinical pathology 57 (6), 591-597, 2004
3022004
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ...
Modern Pathology 28 (11), 1481-1491, 2015
2882015
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a …
RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ...
The Lancet 401 (10391), 1853-1865, 2023
2582023
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20